[go: up one dir, main page]

EA201991227A1 - ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20 - Google Patents

ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20

Info

Publication number
EA201991227A1
EA201991227A1 EA201991227A EA201991227A EA201991227A1 EA 201991227 A1 EA201991227 A1 EA 201991227A1 EA 201991227 A EA201991227 A EA 201991227A EA 201991227 A EA201991227 A EA 201991227A EA 201991227 A1 EA201991227 A1 EA 201991227A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
bind
antigen binding
binding molecules
human
Prior art date
Application number
EA201991227A
Other languages
Russian (ru)
Inventor
Эрик Смит
Николас Дж. Пападопулос
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201991227A1 publication Critical patent/EA201991227A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к антителам, которые связываются с CD3, и к способам их использования. Согласно определенным вариантам осуществления антитела по изобретению связываются с CD3 человека с высокой аффинностью и индуцируют пролиферацию T-клеток человека. Изобретение относится к антителам, которые связываются с CD3 и индуцируют опосредованный T-клетками цитолиз опухолевых клеток. Согласно определенным вариантам осуществления настоящее изобретение относится к биспецифическим антигенсвязывающим молекулам, содержащим первый антигенсвязывающий домен, который специфически связывается с CD3 человека, и вторую антигенсвязывающую молекулу, которая специфически связывается с CD20 человека. В определенных вариантах осуществления биспецифические антигенсвязывающие молекулы по настоящему изобретению способны ингибировать рост B-клеточных опухолей, экспрессирующих CD20. Антитела и биспецифические антигенсвязывающие молекулы по изобретению подходят для лечения заболеваний и нарушений, при которых желательным и/или терапевтически эффективным является активированный или индуцированный целевой иммунный ответ. Например, антитела по изобретению подходят для лечения различных злокачественных опухолей, а также других связанных с CD20 заболеваний и нарушений.The present invention relates to antibodies that bind to CD3, and to methods for using them. In certain embodiments, the antibodies of the invention bind to human CD3 with high affinity and induce proliferation of human T cells. The invention relates to antibodies that bind to CD3 and induce T-cell mediated tumor cell cytolysis. In certain embodiments, the present invention relates to bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds to human CD3, and a second antigen binding molecule that specifically binds to human CD20. In certain embodiments, the bispecific antigen binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. Antibodies and bispecific antigen binding molecules of the invention are suitable for the treatment of diseases and disorders in which an activated or induced target immune response is desirable and / or therapeutically effective. For example, the antibodies of the invention are suitable for the treatment of various malignant tumors, as well as other CD20 related diseases and disorders.

EA201991227A 2013-05-24 2013-09-19 ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20 EA201991227A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361827098P 2013-05-24 2013-05-24

Publications (1)

Publication Number Publication Date
EA201991227A1 true EA201991227A1 (en) 2020-02-28

Family

ID=69636657

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991227A EA201991227A1 (en) 2013-05-24 2013-09-19 ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20

Country Status (1)

Country Link
EA (1) EA201991227A1 (en)

Similar Documents

Publication Publication Date Title
JOP20200237A1 (en) Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
EA201890368A1 (en) ANTIBODIES AGAINST PSMA, BISPECIFIC ANTIGENSELATING MOLECULES THAT BIND PSMA AND CD3 AND THEIR APPLICATION
EA201691858A1 (en) ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS
EA201890785A1 (en) OPTIMIZED BISPECIFIC ANTI-CD3 ANTIBODIES AND THEIR APPLICATION
EA202191580A1 (en) SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION
EA201990781A1 (en) ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION
MY197218A (en) Multispecific antigen-binding molecules and uses thereof
MX2022012083A (en) Multispecific antigen-binding molecules and uses thereof.
EA201490957A1 (en) TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES WITH ANTI-CXCR4 ANTIBODY
MX2021015271A (en) Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation.
EA201991227A1 (en) ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20
EA202090303A2 (en) COMPOSITIONS OF ANTIBODIES FOR TREATMENT OF TUMORS
EA202190089A1 (en) SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONS
EA202190314A1 (en) BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES AND METHODS OF THEIR APPLICATION
EA201990779A1 (en) SPECIFIC ANTI-MUC16-CD3 ANTIBODIES AND CONJUGATES ANTI-MUC16-MEDICINE
AR099798A1 (en) METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT